The latest forecast for 2021: these 10 medicines sell best (list attached)

The latest forecast for 2021, these varieties sell well

Recently, Nature Reviews Drug Discovery published its forecast of the TOP10 global best-selling drugs in 2021.

Judging from the forecast data compiled by Yao Chunqiu, it is still adalimumab, pembrolizumab and lenalidomide ranking the top three.

(Image source: Yao Chunqiu)

In addition, apixaban, aflibercept, nivolumab, and bikampinol have risen in the rankings to varying degrees due to higher growth rates.

1.

Statistics currently show that from the approval of listing in 2003 to the end of June 2020, Humira has brought AbbVie a total of US$165.

Some research institutions have predicted that Xiu Meile’s expected sales by 2021 will be close to 20 billion U.

It is closely followed by Merck’s core product K medicine.

The third place is relatively stable.

With the continuous increase of new indications and the increase in sales year by year, lenalidomide has become the number one blockbuster drug for small molecule anti-tumor drugs.

However, this variety also faces hidden worries: From the domestic market, Meinenet data shows that in 2019, it will be used in Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals and Chinese cities.

To a certain extent, this is a problem that this variety must face-the market exclusivity period of lenalidomide will end in 2022, and subsequent growth is a problem that BMS must face.

2.

Data show that the total sales of Ibrutinib in the six years since its listing has reached US$23.

This is also the first time that Ibrutinib surpassed rituximab to occupy the top position in the market, becoming the fastest growing product in the leukemia field.

However, Ibrutinib is also facing the impact of the second-generation BTK inhibitor, which will make its ranking decline in the sales forecast for 2021.

According to Yao Chunqiu's analysis, if the second generation can successfully resolve the C481S resistance mutation in BTK, the sales growth of Yike may slow down.
In the domestic market, in addition to AbbVie/J&J’s Yike obtained import approval, nearly 10 domestic companies have applied, including Chia Tai Tianqing, Shandong Xinlu, Huadong Pharmaceutical, Hisun Pharmaceutical, and Shanghai Huilun.

Whether this variety can successfully enter the ranks of tens of billions of blockbuster varieties in the future remains to be seen.

In general, compared with the ranking of sales data in 2020, the forecast rankings of major varieties in 2021 are still relatively stable, and tumors are still the fastest attracting area.